Dr Tom Stinchcombe gives his thoughts on the latest developments in other therapies treatments in lung cancer from ASCO Direct Highlights 2022, which target the following mutations: MET exon 14, c-MET, BRAF, KRAS, RET, NTRK and NRG1.

Dr Stinchcombe concludes by highlighting the need for broad-based testing to detect these mutations in lung cancer patients.